Sign up online today & collaborate
or click here to find out more
Oxford, UK – Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and
SMT C1100 is a potential disease-modifying therapy for all patients with DMD and is progressing in its current formulation into a Phase 2 proof of concept clinical trial.
“These initial data are encouraging regarding the potential development of an improved formulation that could achieve blood levels of SMT C1100 that are above those observed with our current formulation,” said Ralf Rosskamp, MD, Chief Medical Officer of Summit. “We have seen in a prior Phase 1 clinical trial how a balanced diet enables our current formulation to reach blood levels that we believe could provide therapeutic benefit, and our ongoing new formulation development work could provide more insight into the potential benefits of SMT C1100 on utrophin modulation in patients with DMD.”
The new formulation Phase 1 clinical trial of SMT C1100 is proceeding to evaluate a higher dose of the new formulation. Firm decisions on further development of this new formulation will await full data from the trial.
|Company||Summit Therapeutics plc|